News | June 16, 2022
Glenmark becomes the first company to launch Indacaterol + Mometasone FDC for asthma in India
Glenmark is the first company in India to market the innovative FDC of Indacaterol
Glenmark is the first company in India to market the innovative FDC of Indacaterol
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
'Hello Skin' has been developed in collaboration with the IADVL (Indian Association of Dermatologists, Venereologists and Leprologists)
A total of five observations for Goa and 17 for Monroe
According to IQVIA sales data for the 12-month period ending March 2022, the Zytiga tablets, 500 mg market achieved annual sales of approximately US $ 260.2 million
Glenmark's current portfolio consists of 174 products authorized for distribution in the U.S. marketplace and 48 ANDA's pending approval with the USFDA
Glenmark Pharmaceuticals won Innovation of the Year award
The innovative Fixed-Dose Combination will help improving the glycemic control among adult patients with insulin resistance, those whose diabetes is uncontrolled by metformin; and also those who require addition of Teneliglitptin and Pioglitazone as separate drugs.
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
The company plans to launch the product immediately
Subscribe To Our Newsletter & Stay Updated
